Daiichi Sankyo to use India-based subsidiary to distribute drug

TOKYO Daiichi Sankyo will use a generic drug maker it acquired months ago to distribute one of its hypertension drugs in India, the Japanese drug maker announced Tuesday.

Daiichi will allow Gurgaon, India-based Ranbaxy to promote and market Olvance (olmesartan medoxomil) for the Indian market under a licensing agreement.

“The launch of Olvance is a historic moment in the collaboration between Ranbaxy and Daiichi Sankyo,” Ranbaxy chairman, CEO and managing director Malvinder Mohan Singh said. “This marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India.”